The average Adjusted Symptom Score, a new primary efficacy end‐point for specific allergen immunotherapy trials

J.‐m. Grouin, Éric Vicaut, Stéphanie Jean-Alphonse, Pascal Demoly, Ulrich Wahn, A. Didier, Olivier Beaumont, A. Montagut, M. Le Gall, Philippe DevillierClinical 2011 · DOI

Abstract

The average AdSS can be a valuable alternative to the ARTSS as a primary efficacy end-point in grass pollen allergic rhinoconjunctivitis trials. By adjusting the RTSS for rescue medication use, the AdSS can estimate symptom severity and the treatment effect more accurately. The AdSS is now being tested prospectively in large clinical trials.
BibTeX
@inproceedings{grouin2011average,
  author = {J.‐M. Grouin and Éric Vicaut and Stéphanie Jean-Alphonse and Pascal Demoly and Ulrich Wahn and A. Didier and Olivier Beaumont and A. Montagut and M. Le Gall and Philippe Devillier},
  title = {{The average Adjusted Symptom Score, a new primary efficacy end‐point for specific allergen immunotherapy trials}},
  booktitle = {Clinical},
  year = {2011},
  doi = {10.1111/j.1365-2222.2011.03700.x},
}

Loading related content...

Figure